| Stephen Harry Phillips Ii, DO | |
|
905 University Dr, State College, PA 16801-6626 | |
| (814) 238-8418 | |
| (814) 234-2888 |
| Full Name | Stephen Harry Phillips Ii |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 12 Years |
| Location | 905 University Dr, State College, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508123407 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | OS018632 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mount Nittany Medical Center | State college, PA | Hospital |
| Penn Highlands Huntingdon | Huntingdon, PA | Hospital |
| Upmc Altoona | Altoona, PA | Hospital |
| Penn Highland Dubois | Dubois, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mount Nittany Medical Center Health Services Inc | 8426136797 | 196 |
News Archive
CANCER RESEARCH UK scientists have developed a system to identify faulty or missing genes that could prevent specific chemotherapy regimes from working. This opens the doors for targeted breast cancer treatment, according to research published in the Lancet Oncology* today (Monday).
Hanger Orthopedic Group, Inc. announced today the pricing of the previously announced public offering of 2,000,000 shares of its common stock by Ares Corporate Opportunities Fund, L.P. at a public offering price of $20.00 per share. The transaction is expected to close on December 15, 2010. The shares sold were a portion of the currently outstanding shares issued to Ares in August 2008 in connection with the conversion of all of Hanger's Series A Convertible Preferred Stock into common stock.
Cardiovascular Systems, Inc. (CSI), has received Food and Drug Administration (FDA) conditional Investigational Device Exemption (IDE) approval to evaluate the safety and effectiveness of its Diamondback 360® System in the treatment of calcified coronary lesions. With this conditional approval, CSI is authorized to begin its pivotal trial, ORBIT II, in early 2010 and initially enroll up to 100 patients at as many as 50 U.S. sites.
Centers for Disease Control and Prevention (CDC) this week highlighted the risk of Zika infection in eleven Southeastern Asian countries and recommended that pregnant women avoid them wherever possible.
On the first stop of a 10-day tour of Africa, Secretary of State Hillary Clinton stopped at the Phillipe Maguilen Senghor Health Center in Dakar, Senegal, where Awa Marie Coll-Seck, the country's Minister of Health, "explained to Secretary Clinton how these operational centers dramatically improve maternal and child health," according to a post in USAID's "IMPACTblog."
› Verified 6 days ago
| Entity Name | Mount Nittany Medical Center Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164691499 PECOS PAC ID: 8426136797 Enrollment ID: O20081021000240 |
News Archive
CANCER RESEARCH UK scientists have developed a system to identify faulty or missing genes that could prevent specific chemotherapy regimes from working. This opens the doors for targeted breast cancer treatment, according to research published in the Lancet Oncology* today (Monday).
Hanger Orthopedic Group, Inc. announced today the pricing of the previously announced public offering of 2,000,000 shares of its common stock by Ares Corporate Opportunities Fund, L.P. at a public offering price of $20.00 per share. The transaction is expected to close on December 15, 2010. The shares sold were a portion of the currently outstanding shares issued to Ares in August 2008 in connection with the conversion of all of Hanger's Series A Convertible Preferred Stock into common stock.
Cardiovascular Systems, Inc. (CSI), has received Food and Drug Administration (FDA) conditional Investigational Device Exemption (IDE) approval to evaluate the safety and effectiveness of its Diamondback 360® System in the treatment of calcified coronary lesions. With this conditional approval, CSI is authorized to begin its pivotal trial, ORBIT II, in early 2010 and initially enroll up to 100 patients at as many as 50 U.S. sites.
Centers for Disease Control and Prevention (CDC) this week highlighted the risk of Zika infection in eleven Southeastern Asian countries and recommended that pregnant women avoid them wherever possible.
On the first stop of a 10-day tour of Africa, Secretary of State Hillary Clinton stopped at the Phillipe Maguilen Senghor Health Center in Dakar, Senegal, where Awa Marie Coll-Seck, the country's Minister of Health, "explained to Secretary Clinton how these operational centers dramatically improve maternal and child health," according to a post in USAID's "IMPACTblog."
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stephen Harry Phillips Ii, DO 205 N Nice St, Frackville, PA 17931-1313 Ph: () - | Stephen Harry Phillips Ii, DO 905 University Dr, State College, PA 16801-6626 Ph: (814) 238-8418 |
News Archive
CANCER RESEARCH UK scientists have developed a system to identify faulty or missing genes that could prevent specific chemotherapy regimes from working. This opens the doors for targeted breast cancer treatment, according to research published in the Lancet Oncology* today (Monday).
Hanger Orthopedic Group, Inc. announced today the pricing of the previously announced public offering of 2,000,000 shares of its common stock by Ares Corporate Opportunities Fund, L.P. at a public offering price of $20.00 per share. The transaction is expected to close on December 15, 2010. The shares sold were a portion of the currently outstanding shares issued to Ares in August 2008 in connection with the conversion of all of Hanger's Series A Convertible Preferred Stock into common stock.
Cardiovascular Systems, Inc. (CSI), has received Food and Drug Administration (FDA) conditional Investigational Device Exemption (IDE) approval to evaluate the safety and effectiveness of its Diamondback 360® System in the treatment of calcified coronary lesions. With this conditional approval, CSI is authorized to begin its pivotal trial, ORBIT II, in early 2010 and initially enroll up to 100 patients at as many as 50 U.S. sites.
Centers for Disease Control and Prevention (CDC) this week highlighted the risk of Zika infection in eleven Southeastern Asian countries and recommended that pregnant women avoid them wherever possible.
On the first stop of a 10-day tour of Africa, Secretary of State Hillary Clinton stopped at the Phillipe Maguilen Senghor Health Center in Dakar, Senegal, where Awa Marie Coll-Seck, the country's Minister of Health, "explained to Secretary Clinton how these operational centers dramatically improve maternal and child health," according to a post in USAID's "IMPACTblog."
› Verified 6 days ago
Dr. Daniel R Pitts, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 905 University Dr, State College, PA 16801 Phone: 814-238-8418 Fax: 814-234-2888 | |
Scott Geiger, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 905 University Dr, State College, PA 16801 Phone: 814-238-8418 Fax: 814-234-2888 | |
Robert Marshall Wild Jr., M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 905 University Dr, State College, PA 16801 Phone: 814-238-8418 Fax: 814-234-2888 | |
David Oselinsky, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 905 University Dr, Suite 2, State College, PA 16801 Phone: 814-238-8418 Fax: 814-234-2888 | |
Dr. Kwabena S. Ansong, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 200 Scenery Dr, State College, PA 16801 Phone: 814-231-4560 Fax: 814-235-5512 | |
Charles Munford Dalton, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 905 University Dr, State College, PA 16801 Phone: 814-238-8418 Fax: 814-234-2888 |